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Abstract
The aims of our study were to analyse the risk factors for colonization by Extended-spectrum b-lactamases (ESBL)-producing Proteus mirabilis
(ESBL-PM) in rehabilitation patients and to characterize the molecular features of these strains. The study was conducted in two rehabilitation
centres located in Rome, Italy (Fondazione Santa Lucia IRCCS (FSL)), and Tel-Aviv, Israel (Tel-Aviv Sourasky Medical Center (TASMC)).
Carriage of ESBL-PM was surveyed by rectal swabs. Strain typing was performed by pulsed-ﬁeld gel electrophoresis (PFGE). Identiﬁcation of
ESBL genes was done by PCR and sequencing. Patients admitted to the same institutions without ESBL carriage were included as controls. The
study group included 70 and 41 patients from FSL and TASMC, respectively. In FSL, the multivariate analysis identiﬁed severe acute brain injury
(OR = 15, 95% CI = 3.2–69.5, p 0.001), decubitus ulcer (OR = 3.5, 95% CI = 1.2–9.8, p 0.018) and recent treatment with quinolones
(OR = 5.7, 95% CI = 1.07–30.1, p 0.042) as independent risk factors. ESBL-PM carriers stayed longer in the hospital on average and were less
likely to be discharged home. No signiﬁcant risk factor was identiﬁed in TASMC. There were no similarities in PFGE types or ESBL genes
between the ESBL-PM isolates from the two institutions. In both hospitals, a variety of PFGE types existed but a single ESBL type predominated,
namely TEM-92 in FSL (n = 64/70; 91%) and CTX-M-2 in TASMC (n = 37/41; 90%). A new TEM ESBL variant, TEM-177 was identiﬁed in FSL.
The clonal diversity and the predominance of a single ESBL type suggested that horizontal gene transfer played an important role in
dissemination of resistance. The development of a population analysis tool that would allow tracing deeper genetic relationships is required.
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Introduction
Proteus mirabilis is one of the most common agents of urinary
tract infection, in particular among patients with urological
abnormalities [1]. In addition, it is a frequent cause of other
types of hospital-acquired infections, including bacteraemia [2],
meningitis, empyema and osteomyelitis [3]. Along with sporadic
infection cases, nosocomial outbreaks due to P. mirabilis have
been reported since the 1970s [4–6]. Gastrointestinal coloni-
zation is believed to serve as a reservoir for intra-hospital
spread [4]. As with other Enterobacteriaceae, resistance to
cephalosporins, mediated mostly by extended-spectrum b-
lactamases (ESBLs) [5,7,8] or acquired AmpC-type cephalo-
sporinases [9,10], has been spreading in P. mirabilis populations
in many parts of the world. The molecular epidemiology of
ESBL-producing P. mirabilis (ESBL-PM) varies widely between
different countries. In Italy and France TEM-type enzymes,
especially TEM-92, have been the most common [2,7,8],
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whereas in Poland, Israel and Japan the CTX-M types have been
usually observed [5,11–13]. In some countries, such as Greece,
Italy and Poland, AmpC-producing P. mirabilis strains have
disseminated along with those expressing ESBLs [9].
Only a single study designed to look for the speciﬁc risk
factors for ESBL-PM infections has been published so far [2]. In
this study, the clinical and demographic characteristics of
patients with ESBL-PM bacteraemia were compared with those
of the patients with antibiotic-susceptible P. mirabilis infections
in acute-care settings. Previous hospitalization in a nursing
home and use of a bladder catheter were identiﬁed as risk
factors. The study reported here was conducted in two
rehabilitation centres in Italy and Israel, with distinct types of
patient populations (see below). Rehabilitation wards (RWs)
differ signiﬁcantly from acute-care units, as patients are
commonly hospitalized for longer periods, are more ambulant
and may share joint facilities, such as physiotherapy suites or
pools. Thus, the potential for direct patient-to-patient trans-
mission of resistant bacteria may be more signiﬁcant. Because
patients in our study were monitored throughout their
hospitalization by surveillance cultures, we were able to track
the acquisition of ESBL-PM prior to evolution of clinical
infection. Our aims were: (i) to comparatively assess the risk
factors for ESBL-PM carriage in each of the two institutions; (ii)
to reveal the clonal structure and ESBL genes of ESBL-PM
populations; and (iii) to analyse the acquisition-to-admission
ratio for the identiﬁed ESBL-PM clones.
Methods
Hospital settings
This study was a part of the project MOSAR (Mastering
Hospital Antimicrobial Resistance and its Spread into the
Community), a trans-disciplinary network funded by the
European Commission and devoted to combating and con-
trolling resistance in bacteria. The project focused on endemic
and epidemic nosocomial pathogens in high-risk medical units,
including ICUs, RWs and surgery wards in different European
countries and Israel. Here we present a part of the results
from the Work Package 5 (WP5), based on clinical trials in
RWs, and Work Package 2 (WP2), comprising the laboratory
work on bacterial isolates collected during the trials.
The study was conducted in two hospitals. The ﬁrst centre,
Fondazione Santa Lucia IRCCS in Rome, Italy (FSL), consists of
two wards (106 beds together), and admits patients following
spinal, cranial or orthopaedic trauma and with non-traumatic
neurological and orthopaedic disorders. The second centre
comprises two geriatric RWs (50 beds combined) at the Tel-
Aviv Sourasky Medical Center (TASMC) in Tel Aviv, Israel.
These wards admit elderly patients (>65 year of age) for
rehabilitation following acute care admissions due to ortho-
paedic or neurological disorders or because of general
deterioration in condition. The study included patients admit-
ted to the wards between September 2008 and November
2010 and was approved by the ethics committees of FSL and
TASMC.
Design and data collection
This was a prospective case–control study, aimed at examining
risk factors for ESBL-PM carriage among RW patients. Surveil-
lance rectal cultures were collected from all patients at
admission, 2 weeks later, then once monthly, and at discharge.
According to the local infection control policy, contact isolation
was not carried out for ESBL-PM carriers. The following data
were recorded: patient’s age and sex, admission diagnosis,
medical history including underlying conditions and co-mor-
bidities, prior hospital or long-term care facility (LTCF) stay and
its duration, antibiotic treatment during the last month prior to
admission, the presence of medical devices, history of surgery
or other invasive procedures, and the discharge destination.
ESBL-PM carriers and control patients were randomly selected
from the MOSAR database. Molecular typing and identiﬁcation
of ESBL genes were performed on ﬁrst patient-unique isolates
as described below.
Detection of ESBL-PM isolates and their phenotypic
characterization
Rectal swabs were streaked onto the Brilliance ESBL Agar
(Oxoid, Basingstoke, UK). Putative ESBL-producing Enterobac-
teriaceae colonies (one from each morphotype detected) were
identiﬁed according to the manufacturer’s instructions. Pure
cultures were frozen at 80°C and shipped to the MOSAR
ESBL laboratory (National Medicines Institute in Warsaw,
Poland) for deﬁnite identiﬁcation and further analysis. Species
identiﬁcation was carried out using the Vitek 2 system
(bioMerieux, Marcy l’Etoile, France). ESBL production was
veriﬁed using the double-disk synergy test with disks contain-
ing cefotaxime, ceftazidime, cefepime and amoxicillin with
clavulanate on Mueller-Hinton agar plates (Oxoid) that were
unsupplemented and supplemented with 250 mg/L cloxacillin
(Polfa Tarchomin, Warsaw, Poland) as previously described
[14].
Molecular typing of ESBL-PM isolates
For pulsed-ﬁeld gel electrophoresis (PFGE), total DNAs of the
isolates were puriﬁed as described by Struelens et al. [15] and
digested sequentially with NotI and SﬁI restriction enzymes
(New England BioLabs, Beverly, MA, USA) [16]. PFGE types
and subtypes were discerned by the visual analysis using the
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criteria of Tenover et al.[17]. In order to verify the results,
electrophoretic patterns were compared also with the
BioNumerics Fingerprinting software (Version 6.01; Applied
Maths, Sint-Martens-Latem, Belgium), using the Dice coefﬁ-
cient and clustering by UPGMA (unweighted pair group
method with arithmetic mean) with 1% tolerance in band
position differences.
Identiﬁcation of ESBLs and acquired AmpCs
ESBL-PM isolates were subjected to b-lactamase proﬁling by
isoelectric focusing as described previously [18] by using a
Model 111 Mini IEF Cell (Bio-Rad, Hercules, CA, USA).
Identiﬁcation of the ESBL blaCTX-M-1-, blaCTX-M-2-, blaCTX-M-25-
and blaTEM-like genes and the AmpC blaCMY-2-like genes was
done by PCR as previously described [13]. Sequencing of the
genes was performed for representative isolates as reported
[13,19], using sets of consecutive primers speciﬁc for each
gene type. In the case of blaTEM-like genes two types of PCR
products were obtained with standard primers TEM-A and
TEM-B, amplifying the entire gene together with its 5′-adjacent
region [20]. Some isolates produced shorter amplicons of c.
950 bp alone or together with those of the expected size of c.
1100 bp. If both were observed for a single isolate, the two
PCR products were extracted from agarose gels and
sequenced separately.
Plasmid analysis
Plasmid proﬁling was carried out by PFGE of isolates’ total
DNA cut with nuclease S1 (New England Biolabs) [21]. After
electrophoresis, DNA was blotted onto Hybond-N+ (Amer-
sham Pharmacia Biotech, Little Chalfont, UK) and hybridized
with blaTEM-92 or blaCTX-M-2 PCR probes, using the ECL
Random-Prime Labeling and Detection system (Amersham
Pharmacia Biotech). Mating was done with E. coli A15 RifR [18];
transconjugants were selected with 128 mg/L rifampin and
2 mg/L ceftazidime or cefotaxime (Polfa). Plasmid DNA was
puriﬁed with the QIAGEN Plasmid Midi Kit (QIAGEN, Hilden,
Germany) and characterized by PstI (New England Biolabs)
ﬁngerprinting [22] and by PCR-based replicon typing (PBRT)
[23].
Deﬁnitions and data analysis
Risk factors were analysed by comparing the ESBL-PM carriers
with the ESBL-producing Enterobacteriaceae (ESBL-Ent)-negative
group. The analysis was separated for each institution due to the
big differences in the patient populations. ESBL-PM carriers
were divided into ‘admission’ and ‘acquisition’ groups, according
to the ESBL-PM identiﬁcation time: before and after 72 h from
admission, respectively. In cases when the ﬁrst rectal culture
was collected more than 72 h from admission, the acquisition
status was not determined. Data were analysed using the
univariate analysis: continuous variables were compared
between the groups using an unpaired t-test and categorical
parameters were compared using the chi-square test. p-values
of  0.05 were considered as a signiﬁcant difference between
the groups. The multivariate analysis using binary logistic
regression prediction models was constructed using forward
stepwise. All variables that were identiﬁed in the univariate
analysis with a p <0.1 were included in the model, excluding the
length of stay and discharge destination, being regarded as
outcome measures. All data were analysed using the SPSS
software package version 15.0 (SPSS, Chicago, IL, USA).
Nucleotide sequence accession numbers
The blaTEM-177 coding region sequence appeared in the EMBL
database under the accession number FN652295.
Results
Demographic and clinical characteristics of ESBL-PM carriers
at FSL and TASMC
During the study time (from September 2008 to November
2010), 1017 and 1656 patients were admitted to the FSL and
TASMC RWs, respectively. ESBL-PM carriage was identiﬁed in
93 and 113 of these patients, respectively. Of these, 70 and 41
ESBL-PM carriers (111 in total) were selected from FSL and
TASMC, respectively. An additional ESBL-Ent was identiﬁed in
the surveillance cultures of 61 of the 111 patients, most
commonly E. coli (n = 48). As a control, 70 and 40 ESBL-Ent-
negative patients (110 in total) were identiﬁed in FSL and
TASMC, respectively. Complete clinical data were available
only for 61/71 patients in the FSL ESBL-PM carrier group.
Almost all the patients were admitted following a stay in an
acute-care institution (FSL, 93%; TASMC, 95%). The clinical
and demographic characteristics of the patient groups in the
two centres are presented in Table 1. Overall, the FSL patients
were younger than the TASMC patients [55 (95% CI 52–59)
vs. 81 (95% CI 79–83) years, respectively] and had lower rates
of underlying chronic diseases, such as cardiovascular, lung and
renal disease and diabetes, and history of malignancy.
In FSL, the ESBL-PM carriers were more likely to be admitted
following severe acute brain injury (SABI), to have acute
infection upon admission and decubitus ulcer, and to have a
history of urinary catheter or other invasive devices used in the
preceding month, when compared with the control group. Also
they had a higher rate of recent treatment (within 1 month)
with quinolones and aminoglycosides. No signiﬁcant differences
were found in the rates of the recent usage (1 month) of other
antimicrobial agents, including penicillins, b-lactam/b-lactams
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inhibitor combinations, cephalosporins, carbapenems, macro-
lides, glycopeptides, tetracyclines and metronidazole (data not
shown). The FSL ESBL-PM carriers had a longer mean length of
stay (LOS) and were less likely to be discharged home at the
end of their stay. In the multivariate analysis, admission due to
SABI (OR = 15, 95% CI = 3.2–69.5, p 0.001), decubitus ulcer
(OR = 3.5, 95% CI = 1.2–9.8, p 0.018) and recent treatment
with quinolones (OR = 5.7, 95% CI = 1.07–30.1, p 0.042) were
identiﬁed as signiﬁcant risk factors.
In TASMC, the ESBL-PM carriers had a higher mean age,
longer LOS and were more likely to be admitted with acute
infection, but these differences were not statistically signiﬁcant.
Four ESBL-PM carriers but none in the control group were
admitted following spinal cord diseases and injuries (SDI; p
0.043).
Molecular characteristics and acquisition of ESBL-PM in FSL
and TASMC
The PFGE types, ESBLs and acquisition status of all isolates are
presented in Table 2 and Fig. S1. There were no similarities in
the PFGE types or ESBLs between the ESBL-PM populations
from the two institutions. In both centres, a variety of PFGE
types existed (FSL, 21 types; TASMC, 10 types), with a notable
representation of several types. In FSL, 10 types comprised
more than one isolate each, and ﬁve of these, having  5
isolates each, grouped 47/70 (67%) of the overall FSL isolates.
Some types, like FSPmiH (n = 16) or FSPmiB (n = 10), were
diversiﬁed into multiple subtypes, whereas others, like FSPmiG
(n = 10), were homogeneous. In TASMC, ﬁve types grouped
more than one isolate and three of these, TAPmiB (n = 15),
TAPmiA (n = 9) and TAPmiE (n = 8), represented 32/41
(78%) of the isolates, all being highly diverse.
TABLE 1. Clinical and demographic characteristics of ESBL-PM carriers and control groups in Fondazione Santa Lucia IRCCS
(FSL) and Tel-Aviv Sourasky Medical Center (TASMC)
Variable
FSL
p-value
TASMC
p-valueESBL-PM (n = 61) Controls (n = 70) ESBL-PM (n = 41) Controls (n = 40)
Age, mean (95% CI) 52 (46–57) 58 (54–63) 0.068 83 (80–86) 78 (77–82) 0.083
Male (%) 37 (61) 40 (57) NS 20 (50) 14 (35) NS
Acquisition cases, n (%) 25 (40) NA NA 19 (46) NA NA
LTCF stay in last 6 months (%) 10 (16) 6 (9) NS 4 (10) 6 (15) NS
SABI admission, n (%) 20 (33) 2 (3) <0.001 0 0 NS
SDI admission, n (%) 10 (16) 14 (20) NS 4 (10) 0 0.043
Active infection on admission (%) 8 (13) 2 (3) 0.027 5 (12) 1 (2) 0.096
CVD, n (%) 20 (32) 28 (40) NS 34 (83) 35 (87) NS
CHF, n (%) 3 (5) 2 (3) NS 6 (15) 3 (7) NS
CVA/TIA, n (%) 14 (23) 24 (34) NS 10 (24) 6 (15) NS
CLD, n (%) 1 (2) 0 NS 6 (15) 2 (5) NS
RF, n (%) 0 0 NS 6 (15) 9 (22) NS
Diabetes, n (%) 6 (10) 11 (16) NS 13 (32) 17 (42) NS
Decubitus ulcer, n (%) 20 (32) 7 (10) 0.001 0 0 NS
History of malignancy, n (%) 4 (6) 4 (6) NS 13 (32) 12 (30) NS
Urinary catheter/other invasive device, n (%) 42 (69) 34 (49) 0.019 35 (87) 31 (82) NS
Invasive procedure in last year, n (%) 42 (69) 42 (60) NS 24 (58) 22 (55) NS
Antibiotic in the past month, n (%) 21 (34) 16 (23) NS 32 (78) 25 (62) NS
Quinolones in the past month, n (%) 8 (13) 2 (3) 0.027 5 (12) 3 (7) NS
AG in the past month, n (%) 6 (10) 1 (1) 0.033 1 (2) 0 NS
Antibiotic Rx on admission, n (%) 21 (34) 14 (20) 0.063 7 (17) 3 (7) NS
Hospitalization time, days (95% CI) 120 (98–142) 62 (52–72) <0.001 31 (25–38) 25 (20–30) 0.083
Transfer to acute care/LTCF, n (%) 30 (48) 5 (7) <0.001 7 (17) 6 (15) NS
ESBL-PM, extended-spectrum b-lactamase-producing P. mirabilis carriers; LTCF, long-term care facility; SABI, admission due to severe acquired brain injury; SDI, admission due to
spinal cord diseases and injuries; CVD, cardiovascular diseases, including hypertension; CHF, congestive heart failure; CVA/TIA, cerebrovascular accident/transient ischaemic
accident; CLD, chronic lung disease; RF, renal failure; AG, aminoglycosides; NS, non-signiﬁcant; NA, not applicable.
The p-values relate to each institution separately.
TABLE 2. Pulsed-ﬁeld gel electrophoresis (PFGE) typing,
resistance genes and acquisition status of extended-spectrum
b-lactamases (ESBL)-producing P. mirabilis isolates at Fond-
azione Santa Lucia IRCCS (FSL) and Tel-Aviv Sourasky
Medical Center (TASMC)
PFGE typea (n) ESBL-gene (n) PFGE-var.b
Acquisition
status (n)
FSPmiB (10) TEM-92 (10) 3 AD 1, AQ 8, UN 1
FSPmiC (5) TEM-92 (5) 3 AD1, UN 4
FSPmiD (6) TEM-92 (6) 1 AQ 3, UN 3
FSPmiG (10) TEM-92 (10) 1 AD 3, AQ 3, UN 4
FSPmiH (16) TEM-92 (16) 11 AD 7, AQ 5, UN 4
FSPmiM (2) TEM-92 (1) 1 AD 1
CTX-M-15 (1) 1 AD 1
FSPmiN (2) TEM-177 (2) 1 AD 1, AQ 1
FSPmiP (2) TEM-72 (2) 1 AQ 2
FSPmiT (4) TEM-92 (4) 2 AD 4
FSPmiW (2) TEM-92 (2) 1 AD 1, AQ 1
Singletons (11) TEM-92 (10),-72 (1) 11 AD 4, AQ 4, UN 3
FSL total (n = 70) AD 24, AQ 27, UN 19
TAPmiA (9) CTX-M-2 (7) 5 AD 5, AQ 2
CTX-M-25 (1) 1 AQ 1
CTX-M-94 (1) 1 AD1
TAPmiB(15) CTX-M-2 (15) 13 AD 6, AQ 8, UN 1
TAPmiC (2) CTX-M-2 (2) 1 AD 1, AQ 1
TAPmiE (8) CTX-M-2 (8) 6 AD 2, AQ 2, UN 4
TAPmiI (2) CTX-M-2 (2) 1 AQ 2
Singletons (5) CTX-M-2 (3),
-10 (1), -39 (1)
4 AD 2, AQ 3
TASMC total (n = 41) AD 17, AQ 19, UN 5
AD, admission; AQ, acquisition; UN, undetermined status.
aPFGE types are designated according to Fig. S1, with FSL isolates presented ﬁrst.
bNumber of PFGE variance of the given type.
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All but one of the ESBL-PM isolates in FSL produced ESBLs
of the family TEM, mainly TEM-92 [8], found in 64/70 isolates
(91%) of 18/21 PFGE types. The minor variants were TEM-72
[24] and TEM-177, identiﬁed in three and two isolates of
speciﬁc PFGE types, respectively. TEM-177 was a new ESBL
variant and when compared with TEM-1 [25] it had seven
amino-acid substitutions: Q6K, Q39K, E104K, R164S, M182T,
A237T and E240K. The blaTEM-177 gene had an identical
promoter to blaTEM-92 [8], including a 135-bp deletion and a
G162?T mutation when compared with the P3 promoter of
the blaTEM-1A gene [25,26]. Apart from those causing amino-
acid changes, the blaTEM-177 coding region contained three
silent mutations compared with blaTEM-1A [25], namely A346?
G, C436?T and T682?C. Of note, AmpC-producing P. mir-
abilis isolates were recovered from 30 patients in FSL, but not
in TASMC. Carbapenemases were not identiﬁed in any of the
ESBL-PM isolates. A single ESBL-PM isolate from FSL co-
produced the CTX-M-15 ESBL [27] and the CMY-16 AmpC-
like cephalosporinase [9].
In opposition to FSL, all ESBL-PM from TASMC expressed
only CTX-M-type ESBLs, mainly CTX-M-2 [28], identiﬁed in
37/41 isolates (90%) of 8/10 PFGE types. The only exceptions
were four isolates having four different variants of the CTX-M-
25 group, namely CTX-M-25 [29], -39 [30], -94 and -100 [31].
The CTX-M-25 and -94 were produced by the PFGE type
TAPmiA, which included also CTX-M-2-producing isolates.
The plasmid analysis was performed on six TEM-92-
producing isolates from FSL (PFGE types FSPmiB, FSPmiC,
FSPmiD, FSPmiG, FSPmiH and FSPmiT), and four CTX-M-2-
producing isolates from TASMC (types TAPmiA, TAPmiB,
TAPmiC and TAPmiE), each representing a major PFGE type. In
each of the isolates from FSL, the blaTEM hybridization revealed
the presence of the gene on a c. 50 kb plasmid. PstI ﬁngerprints
of these plasmids were identical (results not shown); they were
non-typeable by PBRT and did not self-transfer to E. coli cells. In
TASMC, the blaCTX-M-2-harbouring plasmids were more
diverse. Isolates of two PFGE types (TAPmiA and TAPmiC)
had two copies of the blaCTX-M-2 gene, one chromosomal and
one on a plasmid of c. 200 kb. The plasmids had the same PstI
ﬁngerprint (results not shown), were of the IncA/C type and
were successfully transferred to E. coli. The TAPmiE isolate had
blaCTX-M-2 on a c. 50 kb plasmid (results not shown), which did
not self-conjugate and was probably of the IncFIA type, as
suggested by PBRT performed on DNA from the clinical
isolate. Finally, the TAPmiB isolate had only one chromosomal
copy of the gene (results not shown).
In both centres, the proportions of admission and acquisi-
tion cases were similar (24/27 and 17/19 in FSL and TASMC,
respectively). A single strain, the FSPmiB PFGE type producing
TEM-92, had a signiﬁcantly high number of acquisition to
admission cases, 8 vs. 1 (p <0.05). Comparing the FSPmiB-
carrying patients with the other ESBL-PM carriers in FSL, other
risk factors associated with this strain were not identiﬁed (data
not shown).
Discussion
P. mirabilis has been reported as one of the most frequent
ESBL-Ent species in Italy [2,32,33]. Despite that, there are no
data about the distinct risk factors for ESBL-PM colonization in
Italy or elsewhere. In Israel, as in most of the world, the data
regarding the epidemiology and molecular epidemiology of
ESBL-PM are even more limited [12]. Hence, our study
provides a new outlook on this important pathogen.
The analysis was performed in unique settings of two
rehabilitation centres in Italy and Israel that differed signiﬁ-
cantly in the types of medical services and their patient
populations. These differences were probably responsible for
the differences in risk factors for the ESBL-PM carriage
identiﬁed in each centre. In Italy, ESBL-PM carriers differed in
many aspects from the control group of patients. Several risk
factors that were identiﬁed, including longer LOS and recent
treatment with quinolones, were previously described as risk
factors for other ESBL-Ent infections [34]. The use of an
invasive device was identiﬁed as a risk factor in the univariate
analysis, as reported by Endimiani et al. [2], but previous LTCF
admission was not. We also did not identify recent treatment
with cephalosporins and anti-pseudomonas penicillin as risk
factors, as reported in a retrospective study of nosocomial
multidrug-resistant (MDR) P. mirabilis urinary tract infection
[1]. We identiﬁed admission following SABI as an independent
risk factor. As this feature is unique to that particular
institution (FSL, Rome), it has not been reported or sought
in other studies. Although local spread might have been a
plausible explanation for this ﬁnding, it was not supported by
the polyclonal nature of the ESBL-PM isolates in this group of
patients (data not shown). A unique ﬁnding in our study was
the identiﬁcation of decubitus ulcer as another independent
risk factor. As P. mirabilis is commonly isolated from chronic
wounds [35], this ﬁnding may reﬂect a complex interaction
between the intestinal and the wound ﬂora in these patients. In
the Israeli centre, TASMC, several risk factors were identiﬁed
but, in contrast to FSL, these were statistically non-signiﬁcant
(0.05 < p <0.1). Although it is possible that a larger sampling
number would have allowed us to identify these factors with
better certainty, this observation also reﬂects the relative
homogeneity of the patient populations in these wards.
Several molecular characteristics of the ESBL-PM isolates,
especially regarding the ESBL types, were consistent with the
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previous data from each of the countries. In Italy, TEM-92 and
TEM-72 were originally reported in 2000 [8,24]. In the
following years, TEM-92 was reported as the most common
ESBL in P. mirabilis in both Italy and France [2,7,33,36].
Nevertheless, the predominance of the TEM-like ESBLs, mainly
TEM-92, among the ESBL-PM isolates from FSL, is intriguing,
considering the prevalence of CTX-Ms in Enterobacteriaceae
populations in Europe, including Italy [37–39]. Indeed, the
predominance of the CTX-M enzymes (mainly CTX-M-15 and
-1) was observed among Escherichia coli strains isolated in the
same institution within the MOSAR project [40].
Similarly, a single enzyme (CTX-M-2) was present in 90% of
the isolates from Israel. Previously, CTX-M-2 was the most
common enzyme found in ESBL-PM isolates in Japan [11]. The
molecular data regarding the ESBL-PM in Israel have been
limited to two strains so far, one that produced CTX-M-25
and the other a novel enzyme, CTX-M-41 [12]. CTX-M-2 was
identiﬁed also in E. coli and Enterobacter spp. isolates in TASMC
in the early 2000s [30,41], but in only a few E. coli isolates that
were recently characterized during the MOSAR project (CTX-
M-15 and -27 being the most prevalent) [40]. It is striking that
the P. mirabilis and E. coli populations concurrently present in
both FSL and TASMC were so different in terms of their ESBL
types and that in both places P. mirabilis had a tendency to
maintain the ‘earlier’ enzyme types.
The origin and evolution of the new gene encoding TEM-177
is rather unclear. The 5′-end of the blaTEM-177 gene, including its
promoter and the coding region just beyond the codon
specifying the Q6K substitution, were identical to blaTEM-92.
However, the further region, including the Q39K substitution
and three silent mutations, suggested that blaTEM-177 was rather
of the blaTEM-2 lineage and not of blaTEM-1, as it is in the case of
blaTEM-92. Moreover, none of the genes coding for the TEM
ESBLs known so far (http://www.lahey.org/Studies/) could be
proposed as a direct blaTEM-177 precursor by acquisition of 1–2
mutations. Hence, blaTEM-177 might have arisen by a combination
of recombinatorial (e.g. between blaTEM-92 and a blaTEM-2-related
gene) and mutational events as has been already proposed in the
evolution of other blaTEM genes [42,43].
In contrast to the general uniformity of ESBL types in each of
the centres, the PFGE analysis showed a heterogeneous clonal
structure of their P. mirabilis populations. Similar ﬁndings were
observed in France and Japan [7,11], even in the course of a
single outbreak [5]. Only in one case, the TEM-92-producing
FSPmiB type, was it possible to assign its higher prevalence to
frequent cases of in-centre acquisition. This contrast between
the ESBL uniformity and clonal heterogeneity has two possible
explanations. First, it is possible that most of the isolates at
each centre descended from a common ancestral strain but the
PFGE approach was too discriminatory to allow tracing such
deeper relatedness. Second, it is possible that the populations
were heterogeneous indeed, and thus the ESBL uniformity
arose from the horizontal transfer of the plasmids [7,44,45].
Indeed, plasmid analysis showed that the main P. mirabilis FSL
clones had a common blaTEM-92-harbouring plasmid. The fact
that the conjugation assay with E. coli as recipient failed, may be
explained by a low transfer efﬁciency, below the sensitivity of
the assay, or by a more species-speciﬁc (P. mirabilis) plasmid.
This might be supported also by its non-typeability by PBRT
and the lack of blaTEM-92 in E. coli strains collected from FSL
patients during the same period [40]. On the other hand, the
analysis of the TASMC isolates had shown that the blaCTX-M-2
gene was harboured by different plasmids, as well as in the
chromosome. It is possible that the latter situations arose from
transposition of a blaCTX-M-2-harbouring mobile element from
one plasmid into other DNA replicons. Studying the clonality
and evolution of P. mirabilis would be signiﬁcantly facilitated
upon the application of a population analysis tool that would
allow tracing deeper genetic relationships among the P. mira-
bilis strains, such as multilocus sequence typing (MLST). Such a
typing method, not currently available, would also allow
comparing strains from different countries and identiﬁcation
of possible globally successful clones, such as the sequence type
131 ESBL-producing E. coli [46].
In conclusion, the risk factors for ESBL-PM colonization may
vary widely between different healthcare institutions. An MLST
scheme for deeper P. mirabilis population studies is currently
required for better understanding the clonal structure and the
transmission potential of ESBL-PM clones.
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